Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Menu
Advanced
  • Structure search
  • List search
Wish Lists Wish Lists
Wish Lists Wish Lists
Wish Lists
Cart Cart
Cart Cart
Cart
Sign in
Sign in
Contact us
Catalog of Screening CompoundsScreening LibrariesBuilding BlocksAl/ML Data sets newCreate custom Al/ML model based on your data new1B virtual space new
Advanced
  • Structure search
  • List search
Homepage > Company > Media > Pharma News > 2017 > Global coalition aims to outpace epidemics with new vaccines

Global coalition aims to outpace epidemics with new vaccines

A global coalition of governments, health specialists and philanthropists will launch a new plan on Thursday to "outsmart" future disease epidemics with a fund to prepare and create new vaccines.

Stung by the devastation of West Africa's 2014-2015 Ebola outbreak, which killed more than 11,300 people before an effective vaccine was developed, the coalition is aiming to ensure such deadly outbreaks can't happen again.

John-Arne Rottingen, interim chief executive officer of the Coalition for Epidemic Preparedness Innovations (CEPI), said it is designed as "a global insurance policy against epidemic and pandemic threats".

 CEPI's founders used the World Economic Forum in Davos to announce its launch, with initial funding of $460 million from the governments of Germany, Japan and Norway, the Bill & Melinda Gates Foundation and the Wellcome Trust global health charity.

Bill Gates, co-chair of the Gates Foundation and a leading global health philanthropist, said recent major viral disease epidemics - Ebola and Zika - showed how the world "is tragically unprepared to detect local outbreaks and respond quickly enough to prevent them from becoming global pandemics".

"Without investments in research and development, we will remain unequipped when we face the next threat," he said. "The ability to rapidly develop and deliver vaccines when new unknown diseases emerge offers our best hope to outpace outbreaks, save lives and avert disastrous economic consequences."

The initial commitments mean CEPI has raised nearly half the $1 billion it needs for its first five years. It is now calling for proposals from researchers and companies who want to work on developing shots against its first target diseases - the Middle East Respiratory Syndrome (MERS), Lassa and Nipah viruses.

Rottingen said all these have shown the capacity to spread across borders and become fast-growing outbreaks causing death and illness. CEPI aims to drastically shorten the time it takes to make vaccines to protect against these and other viruses, which can emerge suddenly as global public health threats.

Jeremy Farrar, director of the Wellcome Trust, told Reuters CEPI aims to develop two vaccine candidates against each disease before any epidemic, so they are ready for rapid deployment in field trials if and when an outbreak starts.

He noted that with Ebola, despite huge international efforts to work faster, a vaccine was developed and validated as 100 percent protective only in the final months of the West Africa epidemic, after thousands had been infected and killed in Guinea, Sierra Leone and Liberia.

"This partnership is trying to make sure the horror of Ebola is not forgotten," he said. "There are moments in time that have to be seized."

CEPI is also backed by major pharmaceutical companies, the World Health Organization and the international health charity Médecins Sans Frontières (MSF).

Joanne Liu, head of MSF, welcomed the launch of CEPI but said price, safety and speed were crucial. "For new vaccines to be game changers, they must be developed and tested before outbreaks hit and made accessible and affordable for all communities in times of health crisis," she said.

Reporting by Kate Kelland; Editing by Mark Trevelyan

Davos, Switzerland | Wed Jan 18, 2017

Source: http://www.reuters.com/

 

Read also

UK and US agree on landmark pharma pricing tariff deal
UK and US agree on landmark pharma pricing tariff deal
The UK and US have agreed to keep tariffs on UK pharmaceutical shipments into the US at zero.
Parkinson's drug as basis for new anti-infectives
Parkinson's drug as basis for new anti-infectives
Pseudomonas aeruginosa – one of the most common hospital germs – has sophisticated mechanisms to efficiently infect the human body and evade the immune system or antibiotics.
Modified herpes virus helps destroy glioblastoma in preclinical models
Modified herpes virus helps destroy glioblastoma in preclinical models
Researchers at Mass General Brigham have modified a herpes simplex virus (HSV-1) that stimulates the immune system to attack glioblastoma cells.
Curi Bio: $10 Million Series B Closed To Scale Human-Relevant Preclinical Platforms
Curi Bio: $10 Million Series B Closed To Scale Human-Relevant Preclinical Platforms
Curi Bio has secured a $10 million Series B round led by Seoul-based contract research organization DreamCIS, funding that will accelerate the expansion of the company’s integrated human-relevant pr...
preload
Catalog of Screening Compounds
Screening Libraries
  • Focused and Target Libraries
  • Active Reference Sets
  • Diversity Libraries
  • Preplated libraries
  • Inhibitors and Approved Drugs
  • Natural Compounds
Screening Compounds
Building blocks
Inhibitors and approved drugs
Natural base
Virtual space
Drug Discovery Services
  • AI Kinome Profile
  • Al/ML Data sets
  • Synthetic and Medicinal Chemistry
  • In silico drug design (CADD)
  • Discovery biology
  • ADME, DMPK
  • Functional ex vivo and in vivo models
  • Safety and Toxicology
Company
  • News & Media
  • Сareers
  • Delivery options
  • Contact us
  • Compliance
  • Trends in discovery compounds
  • High Throughput Screening
  • Chemical Vendors
  • Kinases Inhibitors
  • GPCR
  • Aurora libraries
  • Chemical compounds
  • Chemical data base
Contacts
Contact us
ChemDiv
12730 High Bluff Dr, Suite 100
San Diego CA 92130 USA
+1 858-794-4860
chemdiv@chemdiv.com

preload preload preload preload
Payment systems
Policies & Terms
©2025 ChemDiv     ChemistryOnDemand
Payment systems Payment systems
0 items in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company
Catalog of Screening Compounds
Screening Libraries
  • Focused and Target Libraries
  • Active Reference Sets
  • Diversity Libraries
  • Preplated libraries
  • Inhibitors and Approved Drugs
  • Natural Compounds
Screening Compounds
Building blocks
Inhibitors and approved drugs
Natural base
Virtual space
Drug Discovery Services
AI Kinome Profile
Al/ML Data sets
Synthetic and Medicinal Chemistry
In silico drug design (CADD)
Discovery biology
ADME, DMPK
Functional ex vivo and in vivo models
Safety and Toxicology
Company
News & Media
Contact us
Trends in discovery compounds

We use cookies only to remember your preferences and provide better browsing experience. We do not sell user information. Here is our privacy policy.

Accept